In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir

Abstract excerpt

Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to most monoclonal antibody therapies, SARS-CoV-2 resistance to other antivirals including main protease inhibitors such as ensitrelvir is a major public health concern. Here, repeating...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to COVID-19 Clinical Research Studies
• Share to SARS-CoV-2 and COVID-19 Research
• Share to SARS-CoV-2 detection and testing